Press Room

News / Sep 26, 2018

Hovione New Jersey Site Expansion - Opening Ceremony

Hovione invests over €30m in the USA

New Jersey Site Expansion CDMO Continuous Manufacturing | Hovione

On September 26th, 2018, Hovione New Jersey held the Opening Ceremony of the site expansion. This expansion is the result of an investment over €30 million in its R&D Center.

The Mayor of East Windsor, New Jersey, Janice S. Mironov, the Hovione CEO, Guy Villax and the AICEP Commissioner in the USA, Manuel Couto Miranda were present. The new R&D center represents an expansion of the range of Hovione's service offering in the US market and includes state-of-the-art technologies in the particle engineering and continuous manufacturing areas.

 

Learn More:

 

Also in the Press Room

See All

Integrated approach simplifies development, reduces risk, and supports scalable manufacturing. Hovione and Industrial Design Consultancy Ltd.’s (IDC) lead single-use nasal dry powder device is now available for commercial partnerships. Hovione and IDC have completed the device design and established initial device manufacturing and supply capability, enabling pharmaceutical partners to leverage existing capsule filling infrastructure. This approach simplifies development, reduces cost and risk, and helps shorten timelines to the clinic and commercialization. “This milestone marks an important step in the evolution of our collaboration with IDC — from device innovation to a fully integrated intranasal drug delivery platform,” said Márcio Temtem, Ph.D., Vice President, Strategic Business Management, Hovione. “As the industry looks for faster, more reliable ways to bring complex therapies to patients, integration becomes critical. By bringing together nasal particle engineering science, formulation manufacturing and filling, and device technologies into a single offering, we enable a more seamless and predictable development journey, accelerating the path to market for intranasal therapies.” The nasal delivery device enables broad and targeted nasal deposition flexibility while delivering maximum usability and reliability. With a patented design and manufacturing process established, the platform is available for partnering with pharmaceutical companies on an exclusive basis as part of Hovione’s integrated offering for inhalation and nasal drug development and manufacturing. Additionally, IDC’s Managing Director, Stephen Knowles Ph.D., said the companies are now “well-advanced” with the development of a multi-use device to support an even wider range of therapies and patient needs. Read the full article at ContractPharma.com    

Press Clipping

Hovione, IDC Launch Intranasal Drug Delivery Platform

May 07, 2026